Isomorphic Labs vs ElevenLabs

Side-by-side comparison of AI visibility scores, market position, and capabilities

ElevenLabs leads in AI visibility (84 vs 34)
Isomorphic Labs logo

Isomorphic Labs

EmergingHealthcare & Life Sciences

AI Drug Discovery

Alphabet/DeepMind drug discovery spinoff raised $600M from Thrive Capital; Drug Design Engine doubled AlphaFold3 accuracy for molecular design; partnering with major pharma; preparing first clinical trials from AI-directed drug pipeline across multiple therapeutic areas.

AI VisibilityBeta
Overall Score
D34
Category Rank
#6 of 7
AI Consensus
60%
Trend
up
Per Platform
ChatGPT
45
Perplexity
33
Gemini
31

About

Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical candidate selection. Founded in 2021 under CEO Demis Hassabis's vision of using AI to accelerate medicine, Isomorphic operates with the scientific resources and computational infrastructure of DeepMind while functioning as a standalone drug discovery organization. The company's founding mission is to use AI not merely as a tool to assist drug hunters, but as the primary engine of drug design — replacing the slow, expensive, and largely empirical process of traditional medicinal chemistry with AI-directed molecular engineering.\n\nIsomorphic's core platform is the Drug Design Engine, a proprietary AI system built on top of AlphaFold architecture. The Drug Design Engine has achieved landmark performance results, reportedly doubling the accuracy of AlphaFold3 at predicting how small molecules bind to their protein targets — the fundamental problem in structure-based drug design. This capability enables Isomorphic to computationally design molecules predicted to bind their targets with far greater precision than conventional methods, potentially eliminating many of the expensive iterative cycles that make drug development so slow. The company has also established major pharma partnerships with Eli Lilly and Novartis to co-develop drug candidates across multiple therapeutic areas.\n\nIsomorphic raised $600M from Thrive Capital in 2024–2025, bringing substantial private capital alongside its Alphabet backing to accelerate pipeline development. As of 2026, the company is preparing for its first clinical trials — a critical milestone that will test whether its computational drug design predictions translate into human efficacy. With AlphaFold-derived technology at its core, partnerships with two of the world's largest pharmaceutical companies, and over half a billion in funding, Isomorphic Labs represents the most credentialed and well-resourced pure-play AI drug discovery company in existence.

Full profile
ElevenLabs logo

ElevenLabs

ChallengerAI & Machine Learning

Voice AI

$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.

AI VisibilityBeta
Overall Score
A84
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
79
Perplexity
89
Gemini
82

About

ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.

Full profile

AI Visibility Head-to-Head

34
Overall Score
84
#6
Category Rank
#1
60
AI Consensus
64
up
Trend
up
45
ChatGPT
79
33
Perplexity
89
31
Gemini
82
29
Claude
75
30
Grok
88

Capabilities & Ecosystem

Capabilities

Only Isomorphic Labs
AI Drug Discovery
Only ElevenLabs
Voice AI

Integrations

Only ElevenLabs

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.